Antares Pharma (NASDAQ:ATRS) announced its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01, Morningstar.com reports. The firm had revenue of $14.00 million for the quarter, compared to the consensus estimate of $15.44 million. Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The business’s revenue was down 1.4% on a year-over-year basis.
Antares Pharma (ATRS) opened at $2.65 on Wednesday. The company has a quick ratio of 2.89, a current ratio of 3.34 and a debt-to-equity ratio of 0.69. The stock has a market cap of $435.55, a P/E ratio of -24.09 and a beta of 0.23. Antares Pharma has a 1-year low of $1.58 and a 1-year high of $4.09.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Alliancebernstein L.P. purchased a new position in shares of Antares Pharma in the second quarter worth approximately $119,000. First Eagle Investment Management LLC boosted its holdings in shares of Antares Pharma by 150.0% in the third quarter. First Eagle Investment Management LLC now owns 50,000 shares of the specialty pharmaceutical company’s stock worth $162,000 after buying an additional 30,000 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Antares Pharma in the fourth quarter worth approximately $117,000. State Board of Administration of Florida Retirement System boosted its holdings in shares of Antares Pharma by 95.0% in the third quarter. State Board of Administration of Florida Retirement System now owns 59,413 shares of the specialty pharmaceutical company’s stock worth $192,000 after buying an additional 28,940 shares during the last quarter. Finally, Voya Investment Management LLC purchased a new position in shares of Antares Pharma in the second quarter worth approximately $210,000. 35.44% of the stock is currently owned by institutional investors.
WARNING: “Antares Pharma (ATRS) Posts Earnings Results, Beats Expectations By $0.01 EPS” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3261669/antares-pharma-atrs-posts-earnings-results-beats-expectations-by-0-01-eps.html.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.